A Phase 1 interventional study of PF-03084014 and PF-03084014 in Breast Cancer Metastatic, sponsored by Pfizer. Terminated at 16 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 89th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2013, is one of 37 in phase 1, and was the 70th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Pfizer
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 56 · Phase 3 25 · Phase 4 3
First in 1998; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 75 across the 121 interventional studies, 399 across the 56 observational. Of the 145 that completed or were terminated, 94 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
8 of the studies in Breast Neoplasms by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06495164PfizerA Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | 2026-12-30 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 182 studies in Breast Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2
Drug: PF-03084014 · Drug: Docetaxel
Tablet, 10 mg, twice a day
Tablet, 50 mg, twice a day
Tablet, 100 mg, twice a day
Solution for IV infusion 75 mg/m\^2, every 3 weeks
Also known as: Taxotere
Solution for IV infusion 100 mg/m\^2, every 3 weeks
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1
Any DLT event in Cycle 1: Grade 4 neutropenia lasting more than (\>)7 days; febrile neutropenia (Grade more than or equal to \[\>=\] 3 and body temperature \>=38.5 degrees Celsius); Grade \>=3 neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia without bleeding; Grade \>=3 toxicities (except those that had not been maximally treated); Grade 3 prolongation of time from electrocardiogram (ECG) Q wave to the end of the T wave corresponding to electrical systole (QT) corrected for heart rate (QTc) which persisted after correction of reversible causes; delay of 2 weeks in receiving next scheduled cycle due to persisting treatment-related toxicities; and failure to deliver at least 80% of planned dose during first cycle due to treatment-related toxicities.
Time frame: Cycle 1 Days 1-21
Progression-free Survival (PFS) at 6 Months - Expansion Cohort
The period from study entry until disease progression, death or date of last contact. Assessment of response was made using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: Baseline till 6 months post-dose
Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs (TEAEs) are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Causality assessment was made by the investigator. Grading was per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death related to AE.
Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Number of Participants With Laboratory Abnormalities
Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick).
Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Percentage of Participants With Objective Response (OR)
OR was based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 6 weeks from Cycle 2 onwards up to 26 months
Area Under the Concentration-time Curve (AUC) From Time 0 to Time of Last Measured Concentration (AUClast) of PF-03084014 in Dose-finding Cohort
Serum PF-03084014 pharmacokinetic (PK) parameters were calculated following twice daily (BID) doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1).
Time frame: Cycle (C) 1 Days (D) 1, 2, 8, and 21; Day 1 of subsequent cycles and at EOT (max reached: Cycle 12)
AUClast and AUC From Time 0 Extrapolated to Infinite Time (AUCinf) of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Maximum Serum or Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of PF-03084014 in Dose-finding Cohort
Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Cmax of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Time to Cmax (Tmax) of PF-03084014 in Dose-finding Cohort
Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Tmax of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Systemic Clearance (CL) of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Terminal Half-life (t1/2) of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
Volume of Distribution (Vss) of Docetaxel in Dose-finding Cohort
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
Time frame: C1D1, 2, 8, and 21; D1 of subsequent cycles and at EOT (max reached: C12)
AUClast of PF-03084014 in the Expansion Cohort
Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Cmax of PF-03084014 in the Expansion Cohort
Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Tmax of PF-03084014 in the Expansion Cohort
Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Ctrough of PF-03084014 in the Expansion Cohort
Time frame: C1D1, C1D21, and Day 1 of subsequent cycles and at EOT (max reached: C12)
Duration of Response (DR)
Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
Time frame: Baseline up to 28-35 days after treatment discontinuation (up to Day 280)
Number of Participants With QTc Values Meeting Categorical Summarization Criteria
Criteria for categorical summarization of the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT) corrected for heart rate (QTc) using Bazett's correction (QTcB) or Fridericia's correction (QTcF) included: maximum QTcB or QTcF less than or equal to (\<=) 450 milliseconds (msec), 450 to \<=480 msec, 480 to \<=500 msec, more than (\>) 500 msec; maximum QTcB or QTcF changes (increases/decreases) from baseline (BL) less than (\<) 30 msec, 30 to \<60 msec, more than or equal to (\>=) 60 msec.
Time frame: Screening, C1D1, C1D21, Day 1 of subsequent cycles, and EOT (maximum reached: C12)
Percentage Change From Baseline in Notch 1 to 4 Ribonucleic Acid (RNA) in Blood
As PF-03084014 acts on the Notch pathway as an inhibitor, it is of interest to investigate its effects, if any, on the Notch family of receptors, mainly Notch 1-4.
Time frame: C1D1, C1D2, C1D8, C1D21 and EOT (maximum reached: C12)
| Milestone | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Started | 15 | 3 | 11 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 3 | 11 |
| Withdrew: Clinical progression | 1 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 1 |
| Withdrew: Participant started new treatment | 1 | 0 | 1 |
| Withdrew: Participant refused further follow-up | 0 | 0 | 1 |
| Withdrew: Study terminated | 1 | 0 | 0 |
| Withdrew: Objective progression or relapse | 10 | 3 | 8 |
Any DLT event in Cycle 1: Grade 4 neutropenia lasting more than (\>)7 days; febrile neutropenia (Grade more than or equal to \[\>=\] 3 and body temperature \>=38.5 degrees Celsius); Grade \>=3 neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia without bleeding; Grade \>=3 toxicities (except those that had not been maximally treated); Grade 3 prolongation of time from electrocardiogram (ECG) Q wave to the end of the T wave corresponding to electrical systole (QT) corrected for heart rate (QTc) which persisted after correction of reversible causes; delay of 2 weeks in receiving next scheduled cycle due to persisting treatment-related toxicities; and failure to deliver at least 80% of planned dose during first cycle due to treatment-related toxicities.
| participants | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1 | 1 | 1 | 4 |
The period from study entry until disease progression, death or date of last contact. Assessment of response was made using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| months | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 |
|---|---|
| Progression-free Survival (PFS) at 6 Months - Expansion Cohort | 4.1 (1.3 to 8.1) |
An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs (TEAEs) are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Causality assessment was made by the investigator. Grading was per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death related to AE.
| participants | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| All causality TEAEs | 15 | 3 | 11 |
| Treatment-related (TR) TEAEs | 15 | 3 | 11 |
| All causality SAEs | 4 | 3 | 6 |
| TR SAEs | 3 | 3 | 6 |
| Grade 3 or 4 TEAEs, all causality | 15 | 3 | 11 |
| Grade 3 or 4 TEAEs, TR | 15 | 3 | 11 |
| Grade 5 TEAEs, all causality | 1 | 0 | 1 |
| Grade 5 TEAEs, TR | 0 | 0 | 1 |
| Permanent withdrawal due to all causality TEAE(s) | 1 | 1 | 6 |
| Permanent withdrawal due to TR TEAE(s) | 1 | 1 | 4 |
Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick).
| participants | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 15 | 3 | 11 |
OR was based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Percentage of Participants With Objective Response (OR) | 13.3 (1.7 to 40.5) | 0 (0.0 to 70.8) | 18.2 (2.3 to 51.8) |
Serum PF-03084014 pharmacokinetic (PK) parameters were calculated following twice daily (BID) doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1).
| nanogram (ng)*hour (hr)/milliliter (mL) | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| C1D2 | 1779 ± 63 | 1380 ± 57 | 1839 ± 32 |
| C1D21 | 4119 ± 39 | 3234 ± 21 | 5575 ± 59 |
| C2D1 | 1983 ± 53 | NA ± NA | 2652 ± 28 |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| nanogram (ng)*hour (hr)/milliliter (mL) | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| AUClast, C1D1 | 3535 ± 113 | 4082 ± 36 | 2121 ± 49 |
| AUClast, C2D1 | 2377 ± 29 | NA ± NA | 2136 ± 47 |
| AUCinf, C1D1 | NA ± NA | NA ± NA | 2509 ± 63 |
| AUCinf, C2D1 | 2530 ± 30 | NA ± NA | 2929 ± 3 |
Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)
| ng/mL | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Cmax, C1D2 | 884.8 ± 56 | 744.2 ± 51 | 896.6 ± 40 |
| Cmax, C1D21 | 1053 ± 51 | 677.5 ± 37 | 1501 ± 44 |
| Ctrough, C1D21 | 214.7 ± 39 | 170.8 ± 36 | 306.1 ± 72 |
| Cmax, C2D1 | 885.7 ± 95 | NA ± NA | 1100 ± 21 |
| Ctrough, C2D1 | 186.1 ± 42 | NA ± NA | 226.4 ± 65 |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| ng/mL | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Cmax, C1D1 | 3711 ± 183 | 3447 ± 57 | 2103 ± 68 |
| Cmax, C2D1 | 2606 ± 29 | NA ± NA | 1965 ± 35 |
Serum PF-03084014 PK parameters were calculated following BID doses of PF-03084014 given alone (Cycle 1 Day 21) and in combination with docetaxel (Cycle 1 Day 2 and Cycle 2 Day 1)
| hr | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Tmax, C1D2 | 1.00 (0.500 to 1.03) | 1.02 (1.00 to 4.00) | 1.00 (0.500 to 1.03) |
| Tmax, C1D21 | 0.533 (0.417 to 1.00) | 1.00 (0.500 to 4.03) | 0.767 (0.500 to 2.00) |
| Tmax, C2D1 | 0.883 (0.000 to 1.00) | 1.03 (1.00 to 1.05) | 0.992 (0.500 to 1.02) |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| hr | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Tmax, C1D1 | 1.00 (0.500 to 1.05) | 0.917 (0.500 to 1.00) | 0.983 (0.500 to 1.05) |
| Tmax, C2D1 | 1.00 (0.517 to 1.03) | 0.767 (0.533 to 1.00) | 1.00 (0.500 to 1.50) |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| liter (L)/hr | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| CL, C1D1 | NA ± NA | NA ± NA | 55.51 ± 70 |
| CL, C2D1 | 51.97 ± 23 | NA ± NA | 45.40 ± 5 |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| hr | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| t1/2, C1D1 | 18.35 ± NA | 6.555 ± NA | 7.624 ± 5.368 |
| t1/2, C2D1 | 5.500 ± 7.259 | NA ± NA | 14.27 ± 3.420 |
Plasma docetaxel PK parameters were calculated following a 1-hr infusion of docetaxel given alone (Cycle 1 Day 1) and in combination with BID dosing of PF-03084014 (Cycle 2 Day 1)
| L | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Vss, C1D1 | NA ± NA | NA ± NA | 97.34 ± 73 |
| Vss, C2D1 | 57.37 ± 127 | NA ± NA | 231.5 ± 25 |
| ng*hr/mL | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 |
|---|---|
| AUClast, C1D1 | 1098 ± 47 |
| AUClast, C1D21 | 1955 ± 16 |
| ng/mL | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 |
|---|---|
| Cmax, C1D1 | 496.7 ± 70 |
| Cmax, C1D21 | 982.1 ± 20 |
| hr | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 |
|---|---|
| Tmax, C1D1 | 0.983 (0.500 to 1.00) |
| Tmax, C1D21 | 1.00 (0.483 to 1.00) |
| ng/mL | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 |
|---|---|
| Ctrough of PF-03084014 in the Expansion Cohort | 89.22 ± 51 |
Duration of response (DR) defined as time from start of first documented objective tumor response \[Complete Response (CR) or Partial Response (PR)\] to first documented objective tumor progression or death due to any cause, whichever occurs first. DR = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.02. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.
| months | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|
| Duration of Response (DR) | NA | NA |
Criteria for categorical summarization of the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT) corrected for heart rate (QTc) using Bazett's correction (QTcB) or Fridericia's correction (QTcF) included: maximum QTcB or QTcF less than or equal to (\<=) 450 milliseconds (msec), 450 to \<=480 msec, 480 to \<=500 msec, more than (\>) 500 msec; maximum QTcB or QTcF changes (increases/decreases) from baseline (BL) less than (\<) 30 msec, 30 to \<60 msec, more than or equal to (\>=) 60 msec.
| participants | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| QTcB <=450 msec | 7 | 1 | 2 |
| QTcB 450 to <=480 msec | 6 | 1 | 8 |
| QTcB 480 to <=500 msec | 2 | 1 | 1 |
| QTcB >500 msec | 0 | 0 | 0 |
| QTcF <=450 msec | 13 | 2 | 6 |
| QTcF 450 to <=480 msec | 1 | 0 | 5 |
| QTcF 480 to <=500 msec | 1 | 1 | 0 |
| QTcF >500 msec | 0 | 0 | 0 |
| QTcB increase from BL <30 msec | 11 | 3 | 6 |
| QTcB increase from BL 30-<60 msec | 4 | 0 | 5 |
| QTcB increase from BL >=60 msec | 0 | 0 | 0 |
| QTcF increase from BL <30 msec | 14 | 3 | 9 |
| QTcF increase from BL 30-<60 msec | 1 | 0 | 2 |
| QTcF increase from BL >=60 msec | 0 | 0 | 0 |
| QTcB decrease from BL <30 msec | 15 | 3 | 11 |
| QTcB decrease from BL 30-<60 msec | 0 | 0 | 0 |
| QTcB decrease from BL >=60msec | 0 | 0 | 0 |
| QTcF decrease from BL <30 msec | 13 | 3 | 8 |
| QTcF decrease from BL 30-<60 msec | 2 | 0 | 3 |
| QTcF decrease from BL >=60 msec | 0 | 0 | 0 |
As PF-03084014 acts on the Notch pathway as an inhibitor, it is of interest to investigate its effects, if any, on the Notch family of receptors, mainly Notch 1-4.
| percentage change | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Notch 1 RNA, C1D1 | 4.240 ± 0.5164 | 3.990 ± 0.4581 | 4.431 ± 1.1781 |
| Notch 1 RNA, C1D2 | -5.797 ± 11.0169 | -7.358 ± 14.6569 | -10.647 ± 19.1488 |
| Notch 1 RNA, C1D8 | 32.557 ± 22.0342 | 60.199 ± NA | 35.305 ± 19.4523 |
| Notch 1 RNA, C1D21 | 6.118 ± 17.0382 | 17.047 ± 15.6705 | 11.214 ± 7.9496 |
| Notch 1 RNA, EOT | 5.653 ± 12.0722 | 18.066 ± 9.4153 | 4.177 ± 14.6678 |
| Notch 2 RNA, C1D1 | 4.139 ± 0.4344 | 3.856 ± 0.8869 | 4.351 ± 0.7672 |
| Notch 2 RNA, C1D2 | -12.830 ± 8.1864 | -9.617 ± 16.7632 | -15.441 ± 20.3566 |
| Notch 2 RNA, C1D8 | 15.426 ± 22.0876 | 43.069 ± NA | 17.234 ± 18.0896 |
| Notch 2 RNA, C1D21 | 2.161 ± 9.7434 | 9.756 ± 22.6330 | 4.985 ± 7.6829 |
| Notch 2 RNA, EOT | -1.250 ± 11.6223 | 9.478 ± 28.0500 | -1.558 ± 10.9137 |
| Notch 3 RNA, C1D1 | 14.250 ± NA | 14.673 ± NA | 14.765 ± 1.3469 |
| Notch 3 RNA, C1D2 | — | 0.311 ± NA | -1.186 ± 2.9388 |
| Notch 3 RNA, C1D8 | -2.532 ± NA | 4.608 ± NA | -0.154 ± 11.1968 |
| Notch 3 RNA, C1D21 | — | 1.362 ± NA | -11.274 ± 19.4623 |
| Notch 4 RNA, C1D1 | 13.903 ± 0.5575 | 13.228 ± NA | 14.309 ± 1.3340 |
| Notch 4 RNA, C1D2 | — | 12.215 ± NA | 2.484 ± 5.9621 |
| Notch 4 RNA, C1D8 | -13.264 ± 3.5374 | — | -9.427 ± 9.8077 |
| Notch 4 RNA, C1D21 | 0.927 ± NA | 5.616 ± NA | -0.500 ± 6.4382 |
| Notch 4 RNA, EOT | -3.634 ± 9.0629 | 11.821 ± NA | -9.975 ± 9.8833 |
Collected over Baseline up to 28-35 days after treatment discontinuation (up to Day 280). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | — | 4/15 (26.7%) | 15/15 (100%) |
| PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | — | 3/3 (100%) | 3/3 (100%) |
| PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | — | 6/11 (54.5%) | 11/11 (100%) |
| Event | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/15 | 1/3 | 3/11 |
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 1/3 | 0/11 |
| NeutropeniaBlood and lymphatic system disorders | 0/15 | 1/3 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 1/3 | 0/11 |
| VomitingGastrointestinal disorders | 0/15 | 1/3 | 0/11 |
| MastitisInfections and infestations | 0/15 | 1/3 | 0/11 |
| PneumoniaInfections and infestations | 0/15 | 1/3 | 2/11 |
| Intestinal obstructionGastrointestinal disorders | 0/15 | 0/3 | 1/11 |
| SepsisInfections and infestations | 0/15 | 0/3 | 1/11 |
| Septic shockInfections and infestations | 0/15 | 0/3 | 1/11 |
| Event | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 12/15 | 3/3 | 8/11 |
| NauseaGastrointestinal disorders | 11/15 | 3/3 | 8/11 |
| FatigueGeneral disorders | 12/15 | 2/3 | 11/11 |
| PyrexiaGeneral disorders | 4/15 | 3/3 | 4/11 |
| RashSkin and subcutaneous tissue disorders | 3/15 | 3/3 | 6/11 |
| VomitingGastrointestinal disorders | 5/15 | 1/3 | 9/11 |
| DiarrhoeaGastrointestinal disorders | 10/15 | 2/3 | 8/11 |
| AnaemiaBlood and lymphatic system disorders | 10/15 | 1/3 | 5/11 |
| LeukopeniaBlood and lymphatic system disorders | 10/15 | 2/3 | 5/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/15 | 2/3 | 2/11 |
| Age, Continuous(years) | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|---|
| Mean | 53.3 ± 13.9 | 43.3 ± 17.9 | 46.2 ± 12.6 | 49.6 ± 13.9 |
| Sex: Female, Male(Participants) | PF-03084014 100 mg BID + Docetaxel 75 mg/m^2 | PF-03084014 100 mg BID + Docetaxel 100 mg/m^2 | PF-03084014 150 mg BID + Docetaxel 75 mg/m^2 | Total |
|---|---|---|---|---|
| Female | 15 | 3 | 11 | 29 |
| Male | 0 | 0 | 0 | 0 |
Ran from Nov 2013 to primary completion in Dec 2015, 25 months.
Results were first posted in Mar 2019, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirogacestat